Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best undervalued wide moat stocks. Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026 On January 13, 2026, Leerink raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) from $54.00 to $60.00, while reiterating an ‘Outperform’ rating. Highlighting ample pipeline optionality in 2026, the firm noted 12 registration data readouts across eight assets. Most of these assets represent potential new launc ...